Compare GSK plc (GSK) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Halliburton Company — how do they compare? GSK plc trades at $46.82 (market cap $91.88B), while Halliburton Company trades at $32.6 (market cap $27.14B). The key difference: GSK plc is far larger — about 3.4× Halliburton Company's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Halliburton Company for 89 Days on average.
| GSK | HAL | |
|---|---|---|
Market Cap | $91.88B | $27.14B |
Volume | 7,730,529 | 11,258,156 |
Sector | Health | Energy |
52-Week High | $61.18 | $42.98 |
52-Week Low | $43.24 | $21.82 |
Typical Hold Time | 93 Days | 89 Days |
Enterprise Value | $111.88B | $33.29B |
Dividend Yield | 3.9% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Halliburton (HAL) trades at $31.75, down 2.96% on the day, reflecting near-term bearish technical signals despite strong analyst support. The stock shows solid fundamentals with a P/E of 17.05 and consistent earnings beats in recent quarters. Recent news highlights expansion in Venezuela and a new contract in Cyprus, positioning the company for growth in international energy markets. Cash flow trends indicate variability, with 2025 net cash flow negative but projected to turn positive in 2026.
The outlook for HAL is cautiously optimistic, driven by international contracts and analyst consensus pointing to significant upside with a $43.11 price target. Key risks include oil price volatility and execution challenges in new markets. Investment opportunity lies in the company's strategic expansions and robust profitability metrics, though investors should weigh macroeconomic factors affecting the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
